Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03775512 · ClinicalTrials.gov registry record · NA
Evaluation of QDOT MICRO™ Catheter for Pulmonary Vein Isolation in Subjects With Paroxysmal Atrial Fibrillation
A NA study, sponsored by Biosense Webster.
- Completed
- Registry status
- NA
- Development phase
- 283
- Enrollment target
NCT03775512 is a NA study that has completed, run by Biosense Webster. The registered enrollment target is 283 participants.
The verdict
NCT03775512, a NA study, has completed, sponsored by Biosense Webster.
- COMPLETED
- Registry status
- NA
- Development phase
- 283 participants
- Enrollment target
Study Summary
Prospective, non-randomized, pre-market clinical evaluation of the QDOT MICRO™ Catheter to demonstrate the safety and effectiveness when compared to an historical control performance goal.
Interventions
- DEVICE RF Ablation with QDOT Micro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 283 participants |
| Start Date | 2019-01-30 |
| Est. Completion | 2022-02-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03775512
The ClinicalTrials.gov registry entry for NCT03775512 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 283 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biosense Webster, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RF Ablation with QDOT Micro is the first listed.
NCT03775512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03775512 about?
NCT03775512 is a clinical study titled "Evaluation of QDOT MICRO™ Catheter for Pulmonary Vein Isolation in Subjects With Paroxysmal Atrial Fibrillation". Prospective, non-randomized, pre-market clinical evaluation of the QDOT MICRO™ Catheter to demonstrate the safety and effectiveness when compared to an historical control performance goal.
What is the current status of trial NCT03775512?
This trial is currently completed. It is a NA study. The enrollment target is 283 participants. The study started on 2019-01-30. Estimated completion is 2022-02-17.
What interventions are being tested in trial NCT03775512?
The interventions under investigation include: RF Ablation with QDOT Micro (DEVICE).
Who is sponsoring clinical trial NCT03775512?
This trial is sponsored by Biosense Webster, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.